186 related articles for article (PubMed ID: 2369083)
1. Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors.
Schneider MR; Michna H; Nishino Y; Neef G; el Etreby MF
Anticancer Res; 1990; 10(3):683-7. PubMed ID: 2369083
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the progesterone antagonists ZK 98.299 and RU 38.486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and the MNU-induced mammary tumor models of the rat.
Schneider MR; Michna H; Nishino Y; el Etreby MF
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):691-701. PubMed ID: 2497018
[TBL] [Abstract][Full Text] [Related]
3. The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death.
Michna H; Schneider MR; Nishino Y; el Etreby MF
J Steroid Biochem; 1989; 34(1-6):447-53. PubMed ID: 2626038
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies.
Michna H; Schneider MR; Nishino Y; el Etreby MF
Breast Cancer Res Treat; 1989 Dec; 14(3):275-88. PubMed ID: 2514814
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors.
Bakker GH; Setyono-Han B; Henkelman MS; de Jong FH; Lamberts SW; van der Schoot P; Klijn JG
Cancer Treat Rep; 1987 Nov; 71(11):1021-7. PubMed ID: 3119199
[TBL] [Abstract][Full Text] [Related]
6. The antitumor potency of progesterone antagonists is due to their differentiation potential.
Michna H; Gehring S; Kühnel W; Nishino Y; Schneider MR
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):203-10. PubMed ID: 1525061
[TBL] [Abstract][Full Text] [Related]
7. The tumour-inhibiting potential of the progesterone antagonist Onapristone in the human mammary carcinoma T61 in nude mice.
Schneider MR; Michna H; Habenicht UF; Nishino Y; Grill HJ; Pollow K
J Cancer Res Clin Oncol; 1992; 118(3):187-9. PubMed ID: 1548283
[TBL] [Abstract][Full Text] [Related]
8. Progesterone antagonists: tumor-inhibiting potential and mechanism of action.
Michna H; Nishino Y; Neef G; McGuire WL; Schneider MR
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):339-48. PubMed ID: 1562510
[TBL] [Abstract][Full Text] [Related]
9. [Animal experimental models of breast cancer for therapeutic testing of hormones and antihormones].
Naundorf H
Arch Geschwulstforsch; 1988; 58(5):345-56. PubMed ID: 3060043
[TBL] [Abstract][Full Text] [Related]
10. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of the antiestrogen, tamoxifen, ona pregnancy-dependent mouse mammary tumor (TPDMT-4).
Matsuzawa A; Mizuno Y; Yamamoto T
Cancer Res; 1981 Jan; 41(1):316-24. PubMed ID: 7448771
[TBL] [Abstract][Full Text] [Related]
12. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.
Gottardis MM; Jordan VC
Cancer Res; 1987 Aug; 47(15):4020-4. PubMed ID: 3607747
[TBL] [Abstract][Full Text] [Related]
13. [Antitumor activity of miproxifene phosphate (TAT-59) against human mammary carcinoma].
Toko T; Saito H; Fujioka A; Nukatuka M; Sato K; Hashimoto A; Shibata J; Yamada Y
Gan To Kagaku Ryoho; 1998 May; 25(6):829-38. PubMed ID: 9617321
[TBL] [Abstract][Full Text] [Related]
14. Antitumor and chemopreventive effects of a clomiphene analog, MDL 103,323, in mammary carcinoma.
Bitonti AJ; Baumann RJ; Bush TL; Cashman EA; Wright CL; Prakash NJ
Anticancer Res; 1996; 16(5A):2553-7. PubMed ID: 8917350
[TBL] [Abstract][Full Text] [Related]
15. A spontaneous estrogen dependent, tamoxifen sensitive mouse mammary tumor: a new model system to study hormone-responsiveness in immune competent mice.
Simian M; Manzur T; Rodriguez V; de Kier Joffé EB; Klein S
Breast Cancer Res Treat; 2009 Jan; 113(1):1-8. PubMed ID: 18183485
[TBL] [Abstract][Full Text] [Related]
16. Platinum complexes with a selective action on estrogen receptor-positive mammary tumors.
von Angerer E; Birnböck H; Knebel N
Anticancer Drug Des; 1989 Jun; 4(1):21-35. PubMed ID: 2757751
[TBL] [Abstract][Full Text] [Related]
17. Similarities and differences in the ultrastructure of two hormone-dependent and one independent human breast carcinoma grown in athymic nude mice: comparison with the rat DMBA-induced tumor and normal secretory mammocytes.
Anderson WA; Perotti ME; McManaway M; Lindsey S; Eckberg WR
J Submicrosc Cytol; 1984 Oct; 16(4):673-90. PubMed ID: 6438351
[TBL] [Abstract][Full Text] [Related]
18. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
[TBL] [Abstract][Full Text] [Related]
19. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
20. Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse.
Robinson SP; Jordan VC
Cancer Res; 1989 Apr; 49(7):1758-62. PubMed ID: 2522347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
